4.6 Article

Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors

期刊

BLOOD ADVANCES
卷 6, 期 5, 页码 1559-1565

出版社

ELSEVIER
DOI: 10.1182/bloodadvances.2021006470

关键词

-

资金

  1. American Society of Hematology as part of the Hematology Opportunities for the Next Generation of Research Scientists (HONORS) award
  2. National Institutes of Health Heart, Lung, and Blood Institute CLOT Consortium [U01HL143365]
  3. Dana Farber Harvard Cancer Center Core Grant [5P30 CA006516]

向作者/读者索取更多资源

In this study, the influence of antiplatelet agents on the development of brain tumor-associated intracranial hemorrhage (ICH) was analyzed. It was found that the use of antiplatelet agents did not increase the risk of ICH, nor did it affect the incidence, size, or severity of ICH in patients with brain metastases.
Although intracranial hemorrhage (ICH) is frequent in the setting of brain metastases, there are limited data on the influence of antiplatelet agents on the development of brain tumor-associated ICH. To evaluate whether the administration of antiplatelet agents increases the risk of ICH, we performed a matched cohort analysis of patients with metastatic brain tumors with blinded radiology review. The study population included 392 patients with metastatic brain tumors (134 received antiplatelet agents and 258 acted as controls). Non-small cell lung cancer was the most common malignancy in the cohort (74.0%), followed by small cell lung cancer (9.9%), melanoma (4.6%), and renal cell cancer (4.3%). Among those who received an antiplatelet agent, 86.6% received aspirin alone and 23.1% received therapeutic anticoagulation during the study period. The cumulative incidence of any ICH at 1 year was 19.3% (95% CI, 14.1-24.4) in patients not receiving antiplatelet agents compared with 22.5% (95% CI, 15.2-29.8; P = .22, Gray test) in those receiving antiplatelet agents. The cumulative incidence of major ICH was 5.4% (95% CI, 2.6-8.3) among controls compared with 5.5% (95% CI, 1.5-9.5; P = .80) in those exposed to antiplatelet agents. The combination of anticoagulation plus antiplatelet agents did not increase the risk of major ICH. The use of antiplatelet agents was not associated with an increase in the incidence, size, or severity of ICH in the setting of brain metastases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据